BioAtla has launched a formal strategic review and cost-cutting program while rethinking the pace and structure of its clinical...

Fortress Biotech is exiting 2025 and entering 2026 with a string of monetization events that reshape its balance sheet...

Eli Lilly just paid $6.3 billion upfront for Centessa Pharmaceuticals and its sleep disorder pipeline. The price looks steep...

Fortress Biotech just converted a rare pediatric disease priority review voucher into $205 million in cash — while the...

Cue Biopharma has appointed Lucinda Warren as interim president and CEO, effective March 26, 2026, following the departure of...

AnaptysBio will spin off its biopharma operations into First Tracks Biotherapeutics, expected to list as TRAX, with a target...

Humacyte reported fourth-quarter and full-year 2025 results and advanced multiple commercial and clinical fronts for its bioengineered vascular conduit,...

Instil Bio has halted development of AXN-2510 via its wholly owned subsidiary Axion Bio and terminated its related license...

Werewolf Therapeutics has begun a strategic alternatives process, retaining Piper Sandler to evaluate options that include a sale, merger,...

Leonabio has acquired an exclusive global license (excluding Asia and select Middle Eastern countries) to develop and commercialize lasofoxifene,...